NCT04439149 2025-11-21
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)